With the approval and commercial release of multiple CAR‐T cell therapy products, alongside the emergence of large‐scale clinical research and innovative therapies, numerous authoritative medical institutions have formulated a series of recommendations for the prevention and control of infections following CAR‐T cell therapy, particularly for CD19‐targeted treatments. This evidence concerns the gene CD19 and infection.